Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $225

Benzinga Newsdesk www.benzinga.com Positive 58.1%

Neg 0% Neu 0% Pos 58.1%

Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $214 to $225.